HomeHealthAsthma drug may help fight dangerous food allergy in kids: Study

Asthma drug may help fight dangerous food allergy in kids: Study

Asthma drug may help fight dangerous food allergy in kids: Study

New York, Feb 26 (IANS) US researchers have found a drug that is commonly used to treat asthma patients and can also help children with food allergies.

According to a new study led by scientists at the Stanford University and Johns Hopkins University, regular use of omalizumab can protect people from severe allergic responses, such as difficulty breathing, if they accidentally eat a small amount of a food they are allergic to.

Omalizumab, which the US Food and Drug Administration originally approved to treat diseases such as allergic asthma and chronic hives, is an injected antibody that binds and deactivates all types of immunoglobulin E, or IgE, the allergy-causing molecule in the blood and on the body’s immune cells.

Based on the new research, published in the New England Journal of Medicine, the FDA, last week, approved omalizumab for reducing risk of allergic reactions to foods.

“Patients impacted by food allergies face a daily threat of life-threatening reactions due to accidental exposures. The study showed that omalizumab can be a layer of protection against small, accidental exposures,” said lead author Robert Wood, Professor of paediatrics at Johns Hopkins University School of Medicine.

For the study, the team included 177 children with at least three food allergies each, of whom 38 per cent were 1 to 5 years old, 37 per cent were 6 to 11 years old, and 24 per cent were 12 or older.

Two-thirds of the children were randomly assigned to receive omalizumab injections, and one-third received an injected placebo; the injections took place over 16 weeks.

Re-test between weeks 16 and 20 showed that 79 patients (66.9 per cent) who had taken omalizumab could tolerate at least 600 mg of peanut protein, the amount in two or three peanuts, compared with only four patients (6.8 per cent) who had the placebo.

Similar proportions of patients showed improvement in their reactions to the other foods in the study.

About 80 per cent of patients taking omalizumab were able to consume small amounts of at least one allergy-triggering food without inducing an allergenic reaction, 69 per cent of patients could consume small amounts of two allergenic foods and 47 per cent could eat small amounts of all three allergenic foods.

–IANS

rvt/dan

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular